Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.
|
30520566 |
2019 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> FGF-21 levels were significantly higher in subjects with high-grade liver steatosis (<i>P</i> < 0.001).
|
31750276 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significant positive correlation of FGF-21 with ALT, gamma glutamyltransferase (GGT), triglycerides, homeostatic model assessment-insulin resistance (HOMA-IR), the degree of liver steatosis in ultrasound and TILC in <sup>1</sup>H-MRS were found.
|
30921653 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients.
|
30916873 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH.
|
30893110 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD).
|
30848827 |
2019 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the results of the present study revealed a new mechanism underlying the regulation of hepatic ER stress and FGF21 expression induced by EPO; thus, EPO may be considered as a potential therapeutic agent for the treatment of fatty liver and obesity.
|
31173165 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
|
31668386 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In NASH mice, administration of PsTag600-FGF21 reduced hepatic steatosis, fibrosis and inflammation.
|
29870802 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation.
|
29289645 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutive ISR activation in the liver induces FGF21 and confers protection from HFD-induced adiposity, IR, and HS in mice.
|
29698569 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This corresponds to an induction of FGF21, which is required for long-term steatosis protection, as FGF21KO mice are refractory to the improved metabolic effects.
|
29290411 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Berberine attenuated hepatic steatosis and controlled energy balance in mice by inducing autophagy and FGF21.
|
29065221 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concentration of FGF-21 was greater in fatty liver cows, while the concentration of LP-PLA2 and Hb was less.
|
30206404 |
2018 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PsTag600-FGF21 dose-dependently reduced body weight, blood glucose, and insulin and lipid levels and reversed hepatic steatosis.
|
29859019 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that chronic PD retards the development of hypertrigylceridemia and fatty liver in obesity and that this relies on the induction of the hepatokine fibroblast growth factor 21 (FGF21).
|
29751292 |
2018 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Their body weight, glucose-lipid metabolism, inflammation indices, hepatic steatosis and fibroblast growth factor 21 (FGF21) levels were measured.
|
30355361 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
With consumption of HFHS diet, FGF21 deficient mice (FGF21 KO) develop excess fatty liver within 16 weeks.
|
29753678 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACC DKI mice had improved glucose and insulin tolerance and a reduction in body weight, body fat and hepatic steatosis similar to WT mice in response to FGF21 administration.
|
28580278 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Chronic treatment with recombinant FGF21 reduces serum and hepatic triglyceride levels and ameliorates fatty liver in obese mice, through the suppression of the lipogenic gene, Srebp-1.
|
28337713 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was a tendency towards higher levels of hepatic FGF21 mRNA in patients with lobular inflammation and fibrosis and towards lower levels in the case of hepatocyte ballooning and steatosis.
|
28820393 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, estrogen replacement restored hepatic FGF21 levels and reduced hepatic steatosis in HFFD-fed OVX rats.
|
28559436 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fatty liver and FGF21 physiology.
|
28549912 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FGF21 decreases in association with reductions in liver fat, GGT, and FIB4, suggesting that FGF21 is upregulated in the context of steatosis and steatohepatitis and is reduced when these conditions improve.
|
29031905 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that FGF21 can be used for early identification of hepatic steatosis.
|
28698650 |
2017 |